Valneva Stock price

Equities

VLA

FR0004056851

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:35:18 2024-03-28 pm EDT 5-day change 1st Jan Change
3.637 EUR +1.28% Intraday chart for Valneva +9.42% -22.94%
Sales 2024 * 191M 206M Sales 2025 * 237M 256M Capitalization 505M 545M
Net income 2024 * 29M 31.29M Net income 2025 * -31M -33.45M EV / Sales 2024 * 2.72 x
Net Debt 2024 * 14.86M 16.04M Net Debt 2025 * 70.87M 76.47M EV / Sales 2025 * 2.43 x
P/E ratio 2024 *
24.7 x
P/E ratio 2025 *
-56.8 x
Employees 676
Yield 2024 *
-
Yield 2025 *
0.27%
Free-Float 82.89%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.28%
1 week+9.42%
Current month+18.58%
1 month+12.05%
3 months-24.23%
6 months-34.18%
Current year-22.94%
More quotes
1 week
3.31
Extreme 3.314
3.73
1 month
2.95
Extreme 2.95
3.95
Current year
2.95
Extreme 2.95
5.00
1 year
2.95
Extreme 2.95
7.85
3 years
2.95
Extreme 2.95
29.70
5 years
1.78
Extreme 1.784
29.70
10 years
1.78
Extreme 1.784
29.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 13-05-09
Director of Finance/CFO 54 21-07-28
Chief Operating Officer - 21-07-05
Members of the board TitleAgeSince
Director/Board Member - 23-06-20
Director/Board Member 73 13-03-06
Director/Board Member 59 22-06-23
More insiders
Date Price Change Volume
24-03-28 3.637 +1.28% 277,774
24-03-27 3.591 -0.77% 498,528
24-03-26 3.619 +0.58% 610,520
24-03-25 3.598 +4.20% 784,883
24-03-22 3.453 +2.37% 450,094

Real-time Euronext Paris, March 28, 2024 at 12:35 pm EDT

More quotes
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva SE has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure. Revenues from its growing commercial business help fuel the continued advancement of Valneva SE's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.637 EUR
Average target price
8.95 EUR
Spread / Average Target
+146.08%
Consensus
  1. Stock
  2. Equities
  3. Stock Valneva - Euronext Paris